<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">38359836</PMID><DateCompleted><Year>2024</Year><Month>03</Month><Day>11</Day></DateCompleted><DateRevised><Year>2024</Year><Month>03</Month><Day>11</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">2666-6340</ISSN><JournalIssue CitedMedium="Internet"><Volume>5</Volume><Issue>3</Issue><PubDate><Year>2024</Year><Month>Mar</Month><Day>08</Day></PubDate></JournalIssue><Title>Med (New York, N.Y.)</Title><ISOAbbreviation>Med</ISOAbbreviation></Journal><ArticleTitle>Complement dysregulation is a prevalent and therapeutically amenable feature of long COVID.</ArticleTitle><Pagination><StartPage>239</StartPage><EndPage>253.e5</EndPage><MedlinePgn>239-253.e5</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.medj.2024.01.011</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S2666-6340(24)00041-2</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Long COVID encompasses a heterogeneous set of ongoing symptoms that affect many individuals after recovery from infection with SARS-CoV-2. The underlying biological mechanisms nonetheless remain obscure, precluding accurate diagnosis and effective intervention. Complement dysregulation is a hallmark of acute COVID-19 but has not been investigated as a potential determinant of long COVID.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">We quantified a series of complement proteins, including markers of activation and regulation, in plasma samples from healthy convalescent individuals with a confirmed history of infection with SARS-CoV-2 and age/ethnicity/sex/infection/vaccine-matched patients with long COVID.</AbstractText><AbstractText Label="FINDINGS" NlmCategory="RESULTS">Markers of classical (C1s-C1INH complex), alternative (Ba, iC3b), and terminal pathway (C5a, TCC) activation were significantly elevated in patients with long COVID. These markers in combination had a receiver operating characteristic predictive power of 0.794. Other complement proteins and regulators were also quantitatively different between healthy convalescent individuals and patients with long COVID. Generalized linear modeling further revealed that a clinically tractable combination of just four of these markers, namely the activation fragments iC3b, TCC, Ba, and C5a, had a predictive power of 0.785.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">These findings suggest that complement biomarkers could facilitate the diagnosis of long COVID and further suggest that currently available inhibitors of complement activation could be used to treat long COVID.</AbstractText><AbstractText Label="FUNDING" NlmCategory="BACKGROUND">This work was funded by the National Institute for Health Research (COV-LT2-0041), the PolyBio Research Foundation, and the UK Dementia Research Institute.</AbstractText><CopyrightInformation>Copyright &#xa9; 2024 The Author(s). Published by Elsevier Inc. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Baillie</LastName><ForeName>Kirsten</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Division of Infection and Immunity, Cardiff University School of Medicine, University Hospital of Wales, Heath Park, Cardiff CF14 4XN, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Davies</LastName><ForeName>Helen E</ForeName><Initials>HE</Initials><AffiliationInfo><Affiliation>Department of Respiratory Medicine, University Hospital of Wales, Llandough, Penarth CF64 2XX, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Keat</LastName><ForeName>Samuel B K</ForeName><Initials>SBK</Initials><AffiliationInfo><Affiliation>Division of Infection and Immunity, Cardiff University School of Medicine, University Hospital of Wales, Heath Park, Cardiff CF14 4XN, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ladell</LastName><ForeName>Kristin</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Division of Infection and Immunity, Cardiff University School of Medicine, University Hospital of Wales, Heath Park, Cardiff CF14 4XN, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Miners</LastName><ForeName>Kelly L</ForeName><Initials>KL</Initials><AffiliationInfo><Affiliation>Division of Infection and Immunity, Cardiff University School of Medicine, University Hospital of Wales, Heath Park, Cardiff CF14 4XN, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jones</LastName><ForeName>Samantha A</ForeName><Initials>SA</Initials><AffiliationInfo><Affiliation>Department of Respiratory Medicine, University Hospital of Wales, Llandough, Penarth CF64 2XX, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mellou</LastName><ForeName>Ermioni</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Division of Infection and Immunity, Cardiff University School of Medicine, University Hospital of Wales, Heath Park, Cardiff CF14 4XN, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Toonen</LastName><ForeName>Erik J M</ForeName><Initials>EJM</Initials><AffiliationInfo><Affiliation>R&amp;D Department, Hycult Biotechnology, Frontstraat 2A, 5405 PB Uden, the Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Price</LastName><ForeName>David A</ForeName><Initials>DA</Initials><AffiliationInfo><Affiliation>Division of Infection and Immunity, Cardiff University School of Medicine, University Hospital of Wales, Heath Park, Cardiff CF14 4XN, UK; Systems Immunity Research Institute, Cardiff University School of Medicine, University Hospital of Wales, Heath Park, Cardiff CF14 4XN, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Morgan</LastName><ForeName>B Paul</ForeName><Initials>BP</Initials><AffiliationInfo><Affiliation>Division of Infection and Immunity, Cardiff University School of Medicine, University Hospital of Wales, Heath Park, Cardiff CF14 4XN, UK; Systems Immunity Research Institute, Cardiff University School of Medicine, University Hospital of Wales, Heath Park, Cardiff CF14 4XN, UK. Electronic address: morganbp@cardiff.ac.uk.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zelek</LastName><ForeName>Wioleta M</ForeName><Initials>WM</Initials><AffiliationInfo><Affiliation>Division of Infection and Immunity, Cardiff University School of Medicine, University Hospital of Wales, Heath Park, Cardiff CF14 4XN, UK; Systems Immunity Research Institute, Cardiff University School of Medicine, University Hospital of Wales, Heath Park, Cardiff CF14 4XN, UK.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>02</Month><Day>15</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Med</MedlineTA><NlmUniqueID>101769215</NlmUniqueID><ISSNLinking>2666-6340</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>9007-36-7</RegistryNumber><NameOfSubstance UI="D003165">Complement System Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>80295-43-8</RegistryNumber><NameOfSubstance UI="D003179">Complement C3b</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000094024" MajorTopicYN="Y">Post-Acute COVID-19 Syndrome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="N">SARS-CoV-2</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003165" MajorTopicYN="N">Complement System Proteins</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003179" MajorTopicYN="N">Complement C3b</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Translation to patients</Keyword><Keyword MajorTopicYN="N">biomarkers of disease</Keyword><Keyword MajorTopicYN="N">complement system</Keyword><Keyword MajorTopicYN="N">long COVID</Keyword></KeywordList><CoiStatement>Declaration of interests The authors declare no competing interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2023</Year><Month>7</Month><Day>21</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2023</Year><Month>11</Month><Day>9</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>1</Month><Day>22</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>3</Month><Day>11</Day><Hour>6</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>2</Month><Day>16</Day><Hour>0</Hour><Minute>43</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>2</Month><Day>15</Day><Hour>18</Hour><Minute>42</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">38359836</ArticleId><ArticleId IdType="doi">10.1016/j.medj.2024.01.011</ArticleId><ArticleId IdType="pii">S2666-6340(24)00041-2</ArticleId></ArticleIdList></PubmedData></PubmedArticle></PubmedArticleSet>